<DOC>
	<DOCNO>NCT01901627</DOCNO>
	<brief_summary>A multicenter registry explore clinical outcome Chinese adult patient active Ankylosing Spondylitis *AS* treat adalimumab , prescribe accord local label , real world practice</brief_summary>
	<brief_title>A Multicenter Registry Adalimumab Chinese Adult Patients With Active Ankylosing Spondylitis</brief_title>
	<detailed_description>This registry conduct non-interventional setting AS patient use adalimumab China.The primary objective evaluate effectiveness safety adalimumab Chinese AS patient real world clinical practice.The secondary objective 1 ) compare clinical outcome patient without good persistence adalimumab ; 2 ) investigate predict factor good clinical response discontinuation adalimumab .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Adult patient establish diagnosis ankylose spondylitis . 2 . Patients eligible use adalimumab accord local label without contraindication . ( According local label , patient screen active infection , TB , HBV , malignancy CHF prescription adalimumab , patient latent TB start full course antiTB therapy use adalimumab . ) 1.Patients contraindication appropriate use adalimumab accord local label exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Spondylitis , Ankylosing</keyword>
	<keyword>adalimumab</keyword>
	<keyword>Prospective Studies</keyword>
</DOC>